Farmadol tablets №50

Description

Farmadol №50 Storage
active substances: 1 tablet contains acetylsalicylic acid 300 mg, paracetamol 100 mg, caffeine 50 mg;

excipients: citric acid, monohydrate; potato starch; lactose monohydrate; povidone; croscarmellose sodium; microcrystalline cellulose; calcium stearate.

Farmadol №50 Dosage form
Tablets.

Main physical and chemical properties: tablets with a flat surface with a dash and bevel, white or almost white, with a faint specific odor. Marbling and impregnation are allowed on the surface of the tablets.

Farmadol №50 Pharmacotherapeutic group
Analgesics and antipyretics. Acetylsalicylic acid, combinations without psycholeptics.

ATX code N02B A51.

Pharmacological properties

Pharmacodynamics.

Pharmadol® is a combined drug with anti-inflammatory, antipyretic and analgesic effects. The action of the drug is determined by its components.

The antipyretic effect of acetylsalicylic acid is realized through the central nervous system by inhibiting the synthesis of prostaglandin PGE2 in the hypothalamus in response to the action of endogenous pyrogens. Its analgesic efficacy is both peripheral (inhibition of prostaglandin synthesis in the inflammatory focus, prevention of sensitization of pain receptors to mechanical and chemical stimuli) and central (action on the centers of the hypothalamus, without suppressing consciousness by hypnotic effect or lowering the mental threshold).

The analgesic and antipyretic effect of paracetamol is due to the inhibition of prostaglandin synthesis and the predominant effect on the thermoregulatory center in the hypothalamus. It is a much weaker inhibitor of the peripheral system of prostaglandin biosynthesis, which plays an important role in the development of the inflammatory response.

The mechanism of action of caffeine is due to inhibition of phosphodiesterase activity, which leads to the accumulation of cAMP. An important link in the mechanism of action of caffeine is its interaction with purine receptors in the brain. It enhances the analgesic effect of acetylsalicylic acid and paracetamol and accelerates its onset.

Pharmacokinetics.

Not studied.

Indication
Mild or moderate pain (headache, migraine, toothache, neuralgia, arthralgia, primary dysmenorrhea); diseases accompanied by hyperthermic syndrome (as an antipyretic).

Contraindication
Hypersensitivity to the components of the drug, other xanthine derivatives (theophylline, theobromine), other salicylates; history of bronchial asthma caused by salicylates or other nonsteroidal anti-inflammatory drugs (NSAIDs); congenital hyperbilirubinemia, congenital glucose-6-phosphate dehydrogenase deficiency, blood diseases, leukopenia, anemia, thrombosis, thrombophlebitis, acute gastrointestinal ulcers, hemorrhagic diathesis, severe renal failure, severe hepatic insufficiency, severe hepatic insufficiency atherosclerosis, severe coronary heart disease, severe heart failure, severe hypertension, a tendency to vasospasm; acute pancreatitis, prostate hypertrophy, severe diabetes mellitus; states of increased excitement, sleep disorders, epilepsy, hyperthyroidism, glaucoma, alcoholism. The period of use of monoamine oxidase inhibitors (MAOIs), as well as the period of 2 weeks after discontinuation of their use, is contraindicated in patients taking tricyclic antidepressants or beta-blockers. Combination with methotrexate at a dosage of 15 mg / week or more.

Interaction with other medicinal products and other forms of interaction
Contraindicated combinations.

Methotrexate – when used in combination with salicylates at a dose of 15 mg per week or more increases the hematological toxicity of methotrexate due to decreased renal clearance of methotrexate by anti-inflammatory agents and its displacement from binding to plasma proteins, so this combination is contraindicated.

Barbiturates reduce the antipyretic effect of paracetamol.

Due to the content of acetylsalicylic acid, the drug may enhance the hypoglycemic effect of oral antidiabetic drugs.